Inotec AMD, a Cambridge, UK-based maker of mobile medical devices designed to heal chronic, hypoxic wounds, received a venture capital investment of undisclosed amount.
Amadeus Capital Partners provided the financial resources.
The company will use the funds to carry out large scale clinical trials outside the UK and to broaden the scope of application of its innovative NATROX™ family of products, establish commercial agreements and grow its presence internationally.
Established in 2005 by Professor Derek Fray from Cambridge University and Mel Vinton, and led by Trevor Stanley, CEO, Inotec is advancing the compact and wearable NATROX™ system, which provides a continuous supply of pure humidified oxygen to wounds. In preliminary trials, NATROX™ has been shown to reduce the size of chronic wounds substantially within weeks, with a large number of pa-tients’ wounds reaching complete healing.
The system is CE marked and FDA approved.